Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.

Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations.

[1]  E. Melamed,et al.  Hemin-induced apoptosis in PC12 and neuroblastoma cells: Implications for local neuronal death associated with intracerebral hemorrhage , 2009, Neurotoxicity Research.

[2]  G. Schlaug,et al.  Association Between Serum Ferritin Level and Perihematoma Edema Volume in Patients With Spontaneous Intracerebral Hemorrhage , 2008, Stroke.

[3]  L. Schlichter,et al.  Neuron death and inflammation in a rat model of intracerebral hemorrhage: Effects of delayed minocycline treatment , 2007, Brain Research.

[4]  R. Keep,et al.  Mechanisms of brain injury after intracerebral haemorrhage , 2006, The Lancet Neurology.

[5]  D. Tsiapras,et al.  Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. , 2005, European heart journal.

[6]  E. Hall,et al.  Time course of production of hydroxyl free radical after subarachnoid hemorrhage in dogs. , 2004, Life sciences.

[7]  Ted Knox,et al.  The Development of a Method to Measure Head Acceleration and Motion in High-impact Crashes , 2004, Neurosurgery.

[8]  T. Schallert,et al.  Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. , 2003, Journal of neurosurgery.

[9]  R. Regan,et al.  Hemin induces an iron‐dependent, oxidative injury to human neuron‐like cells , 2003, Journal of neuroscience research.

[10]  A. Pelıt,et al.  Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma , 2003, Clinical & experimental ophthalmology.

[11]  R. Regan,et al.  Delayed treatment of hemoglobin neurotoxicity. , 2003, Journal of neurotrauma.

[12]  T. Toki,et al.  Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. , 2001, Biochimica et biophysica acta.

[13]  G. Semenza,et al.  Protection from Oxidative Stress–Induced Apoptosis in Cortical Neuronal Cultures by Iron Chelators Is Associated with Enhanced DNA Binding of Hypoxia-Inducible Factor-1 and ATF-1/CREB and Increased Expression of Glycolytic Enzymes, p21waf1/cip1, and Erythropoietin , 1999, The Journal of Neuroscience.

[14]  S. Panter,et al.  Hemoglobin potentiates excitotoxic injury in cortical cell culture. , 1996, Journal of neurotrauma.

[15]  S. Aykol,et al.  The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage. , 1994, General pharmacology.

[16]  C. Palmer,et al.  Deferoxamine Posttreatment Reduces Ischemic Brain Injury in Neonatal Rats , 1994, Stroke.